4.7 Article

Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis:: a multicentre cohort study

Journal

LANCET NEUROLOGY
Volume 6, Issue 7, Pages 595-603

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(07)70131-X

Keywords

-

Funding

  1. Wellcome Trust [0353521B/92/2] Funding Source: Medline

Ask authors/readers for more resources

Background The relative importance of previous diagnosis and hereditary prothrombotic risk factors for cerebral venous thrombosis (CVT) in children in determining risk of a second cerebral or systemic venous thrombosis (VT), compared with other clinical, neuroimaging, and treatment variables, is unknown. Methods We followed up the survivors of 396 consecutively enrolled patients with CVT, aged newborn to 18 years (median 5.2 years) for a median of 36 months (maximum 85 months). In accordance with international treatment guidelines, 250 children (65%) received acute anticoagulation. with unfractionated heparin or low-molecular weight heparin, followed by secondary anticoaguilation prophylaxis with low-molecular weight heparin or warfarin in 165 (43%). Results of 396 children enrolled, 12 died immediately and 22 (6%) had recurrent VT (13 cerebral; 3%) at a median of 6 months (range 0.1-85). Repeat venous imaging was available in 266 children. Recurrent VT only occurred in children whose first CVT was diagnosed after age 2 years; the underlying medical condition had no effect. In Cox regression analyses, non-administration of anticoagulant before relapse (hazard ratio [HR] 11 (.) 2 95% CI 3(.)4-37 (.) 0; p < 0.0001), persistent occlusion on repeat venous imaging (4(.)1, 1(.)1-14(.)8; p=0(.)032), and heterozygosity for the G20210A mutation in factor II (4(.)3, 1(.)1-16(.)2; p=0(.)034) were independently associated with recurrent VT. Among patients who had recurrent VT, 70% (15) occurred within the 6 months after onset. Conclusion Age at CVT onset, non-administration of anticoagulation, persistent venous occlusion, and presence of G20210A mutation in factor 11 predict recurrent VT in children. Secondary prophylactic anticoagulation should be given on a patient-to-patient basis in children with newly identified CVT and at high risk of recurrent VT. Factors that affect recanalisation need further research.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available